What is the Return on Assets (ROA) of Fusion Pharmaceuticals this year?
The Return on Assets (ROA) of Fusion Pharmaceuticals is -0.33 undefined this year.
Fusion Pharmaceuticals ROA 2024
Fusion Pharmaceuticals ROA
-0.33
Fusion Pharmaceuticals Dividend yield
Ticker
FUSN
ISIN
CA36118A1003
In 2024, Fusion Pharmaceuticals's return on assets (ROA) was -0.33, a -16.97% increase from the -0.4 ROA in the previous year.
Fusion Pharmaceuticals Aktienanalyse
What does Fusion Pharmaceuticals do?
Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative cancer therapies. The company was founded in Canada in 2014 and has since pursued a unique approach to cancer treatment: targeted radiation therapy. Fusion Pharmaceuticals' business model is based on providing cancer patients with an effective and gentle alternative to conventional treatment methods. The company utilizes a novel technology that allows radioisotopes to be specifically targeted to cancer cells. This enables radiation to be applied directly to the affected areas without damaging healthy tissue. Fusion Pharmaceuticals specializes in the development of therapies for solid tumors. The company collaborates with various partners to offer a wide range of treatment options. The key products currently include: - FP-1001: This product is currently in Phase 1 clinical trials and is intended for the treatment of patients with solid tumors. FP-1001 combines a specific antibody molecule with the radioactive isotope Actinium-225 to selectively destroy cancer cells. - FP-2000: This product is currently in the preclinical phase and aims to provide an effective treatment for pancreatic cancer. FP-2000 combines a specific antibody molecule with the radioactive isotope Lutetium-177 and has the potential to improve the survival rate of patients with this severe disease. - FP-3000: This product is also in the preclinical phase and is intended for the treatment of prostate cancer. FP-3000 combines a specific antibody molecule with the radioactive isotope Copper-67 and has the potential to offer an effective alternative to conventional treatments such as chemotherapy. Fusion Pharmaceuticals has rapidly gained importance in recent years and has attracted numerous prestigious investors. These include Canadian investment firm OrbiMed Advisors LLC and renowned US biotechnology company Johnson & Johnson. The company has also received several awards, including the Innovation Award from the Canadian government in 2019. For the future, Fusion Pharmaceuticals plans to further expand its development pipeline and create new therapies for a wide range of cancer diseases. The company aims to provide cancer patients worldwide with new hope and an effective alternative to conventional treatment methods. Fusion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Fusion Pharmaceuticals's Return on Assets (ROA)
Fusion Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Fusion Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Fusion Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Fusion Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Fusion Pharmaceuticals Stock
What was the ROA of Fusion Pharmaceuticals compared to the previous year?
The ROA of Fusion Pharmaceuticals has increased by -16.97% compared to the previous year.
What consequences do high ROA have for investors of Fusion Pharmaceuticals?
A high ROA is advantageous for investors of Fusion Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Fusion Pharmaceuticals?
A low ROA can be unfavorable for investors of Fusion Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Fusion Pharmaceuticals affect the company?
An increase in ROA of Fusion Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Fusion Pharmaceuticals impact the company?
A reduction in the ROA of Fusion Pharmaceuticals can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Fusion Pharmaceuticals?
Some factors that can influence the ROA of Fusion Pharmaceuticals include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Fusion Pharmaceuticals important for investors?
The ROA of Fusion Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Fusion Pharmaceuticals take to improve ROA?
To improve ROA, Fusion Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Fusion Pharmaceuticals pay?
Over the past 12 months, Fusion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharmaceuticals is expected to pay a dividend of 0 USD.
What is the dividend yield of Fusion Pharmaceuticals?
The current dividend yield of Fusion Pharmaceuticals is .
When does Fusion Pharmaceuticals pay dividends?
Fusion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Fusion Pharmaceuticals?
Fusion Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Fusion Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Fusion Pharmaceuticals located?
Fusion Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Fusion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Fusion Pharmaceuticals from 5/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/18/2024.
When did Fusion Pharmaceuticals pay the last dividend?
The last dividend was paid out on 5/18/2024.
What was the dividend of Fusion Pharmaceuticals in the year 2023?
In the year 2023, Fusion Pharmaceuticals distributed 0 USD as dividends.
In which currency does Fusion Pharmaceuticals pay out the dividend?
The dividends of Fusion Pharmaceuticals are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Fusion Pharmaceuticals
Our stock analysis for Fusion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Fusion Pharmaceuticals Revenue
- Fusion Pharmaceuticals Net Income
- Fusion Pharmaceuticals P/E
- Fusion Pharmaceuticals P/S
- Fusion Pharmaceuticals EBIT
- Fusion Pharmaceuticals Dividend
- Fusion Pharmaceuticals Stocks
- Fusion Pharmaceuticals Market capitalization
- Fusion Pharmaceuticals Debt
- Fusion Pharmaceuticals Liabilities
- Fusion Pharmaceuticals Equity
- Fusion Pharmaceuticals AAQS
- Fusion Pharmaceuticals Employees
- Fusion Pharmaceuticals ROE
- Fusion Pharmaceuticals ROA
- Fusion Pharmaceuticals ROCE
